UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 66

Sortiert nach

HACER: an atlas of human active enhancers to interpret regulatory variants

Nucleic acids research, 2019-01, Vol.47 (D1), p.D106

2019

Volltextzugriff (PDF)

HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium

Cancer, 2017-11, Vol.123 (21), p.4099-4105

2017

Volltextzugriff (PDF)

MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium

Journal of thoracic oncology, 2019-09, Vol.14 (9), p.1666-1671

2019

Volltextzugriff (PDF)

Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience

Journal of thoracic oncology, 2015-05, Vol.10 (5), p.768-777

2015

Volltextzugriff (PDF)

Clinicopathologic Predictors of Sentinel Lymph Node Metastasis in Thin Melanoma

Journal of clinical oncology, 2013-12, Vol.31 (35), p.4387-4393

2013

Volltextzugriff (PDF)

Features of tumor-microenvironment images predict targeted therapy survival benefit in patients with EGFR-mutant lung cancer

The Journal of clinical investigation, 2023-01, Vol.133 (2), p.1-9

2023

Volltextzugriff (PDF)

Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience

Journal of thoracic oncology, 2019-05, Vol.14 (5), p.876-889

2019

Volltextzugriff (PDF)

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs

JAMA : the journal of the American Medical Association, 2014-05, Vol.311 (19), p.1998

2014

Volltextzugriff (PDF)

The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2)

Clinical cancer research, 2018-03, Vol.24 (5), p.1038-1047

2018

Volltextzugriff (PDF)

Utilization and Influence of Online Support Communities in Idiopathic Subglottic Stenosis Patients

The Laryngoscope, 2021-08, Vol.131 (8), p.1821-1827

2021

Volltextzugriff (PDF)

Scientific Rigor in the Age of COVID-19

JAMA oncology, 2021-02, Vol.7 (2), p.171

2021

Volltextzugriff (PDF)

Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium

Cancer, 2015-02, Vol.121 (3), p.448-456

2015

Volltextzugriff (PDF)

Association between Estrogen Exposure and Idiopathic Subglottic Stenosis

The Laryngoscope, 2024-02, Vol.134 (2), p.825-830

2024

Volltextzugriff (PDF)

Follow-up Interactive Long-Term Expert Ranking (FILTER): a crowdsourcing platform to adjudicate risk for survivorship care

JAMIA open, 2021-10, Vol.4 (4), p.ooab090-ooab090

2021

Volltextzugriff (PDF)

Effect of expanded genomic testing in lung adenocarcinoma (LUCA) on survival benefit: The Lung Cancer Mutation Consortium II (LCMC II) experience

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.11510-11510

2016

Volltextzugriff (PDF)

Barrett's Esophagus Translational Research Network (BETRNet): The Pivotal Role of Multi-institutional Collaboration in Esophageal Adenocarcinoma Research

Gastroenterology (New York, N.Y. 1943), 2014-06, Vol.146 (7), p.1586-1590

2014

Volltextzugriff (PDF)

Fission yeast dim1+ encodes a functionally conserved polypeptide essential for mitosis

The Journal of cell biology, 1997-06, Vol.137 (6), p.1337-1354

1997

Volltextzugriff (PDF)

Oncologist participation in pilot testing a crowdsourcing platform to build a survivorship care risk model

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e13568-e13568

2022

Volltextzugriff (PDF)

Differential pre-malignant programs and microenvironment chart distinct paths to malignancy in human colorectal polyps

Cell, 2021-12, Vol.184 (26), p.6262-6280.e26

2021

Volltextzugriff (PDF)

Comparative Treatment Outcomes for Patients With Idiopathic Subglottic Stenosis

JAMA otolaryngology-- head & neck surgery, 2020-01, Vol.146 (1), p.20

2020

Volltextzugriff (PDF)

Phase I/II study of vorolanib plus nivolumab in patients with thoracic malignancies: immunotherapy (IO) correlatives to differentiate responders from nonresponders

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e21019-e21019

2020

Volltextzugriff (PDF)

LCMC LEADER neoadjuvant screening trial: LCMC4 evaluation of actionable drivers in early-stage lung cancers

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS8596-TPS8596

2022

Volltextzugriff (PDF)

Phase I/II study of nivolumab plus vorolanib in patients with thoracic malignancies: Interim efficacy of the SCLC and primary refractory NSCLC cohorts, and safety data across all cohorts

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.2578-2578

2021

Volltextzugriff (PDF)

The Schizosaccharomyces pombe dim1 + Gene Interacts with the Anaphase-Promoting Complex or Cyclosome (APC/C) Component lid1 + and Is Required for APC/C Function

Molecular and Cellular Biology, 1999-04, Vol.19 (4), p.2535-2546

1999

Volltextzugriff (PDF)

Characteristics and outcomes of patients (pts) with metastatic KRAS mutant lung adenocarcinomas: Lung Cancer Mutation Consortium (LCMC) database

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.9021-9021

2017

Volltextzugriff (PDF)

1 – 25 von 66

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(62)
Mit Volltextzugriff
(57)

Publikationsform

Artikel
(66)

Sprache

Englisch
(66)
Japanisch
(18)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

HACER: an atlas of human active enhancers to interpret regulatory variants

HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium

MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium

Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience

Clinicopathologic Predictors of Sentinel Lymph Node Metastasis in Thin Melanoma

Features of tumor-microenvironment images predict targeted therapy survival benefit in patients with EGFR-mutant lung cancer

Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs

The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2)

Utilization and Influence of Online Support Communities in Idiopathic Subglottic Stenosis Patients

Scientific Rigor in the Age of COVID-19

Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium

Association between Estrogen Exposure and Idiopathic Subglottic Stenosis

Follow-up Interactive Long-Term Expert Ranking (FILTER): a crowdsourcing platform to adjudicate risk for survivorship care

Effect of expanded genomic testing in lung adenocarcinoma (LUCA) on survival benefit: The Lung Cancer Mutation Consortium II (LCMC II) experience

Barrett's Esophagus Translational Research Network (BETRNet): The Pivotal Role of Multi-institutional Collaboration in Esophageal Adenocarcinoma Research

Fission yeast dim1+ encodes a functionally conserved polypeptide essential for mitosis

Oncologist participation in pilot testing a crowdsourcing platform to build a survivorship care risk model

Differential pre-malignant programs and microenvironment chart distinct paths to malignancy in human colorectal polyps

Comparative Treatment Outcomes for Patients With Idiopathic Subglottic Stenosis

Phase I/II study of vorolanib plus nivolumab in patients with thoracic malignancies: immunotherapy (IO) correlatives to differentiate responders from nonresponders

LCMC LEADER neoadjuvant screening trial: LCMC4 evaluation of actionable drivers in early-stage lung cancers

Phase I/II study of nivolumab plus vorolanib in patients with thoracic malignancies: Interim efficacy of the SCLC and primary refractory NSCLC cohorts, and safety data across all cohorts

The Schizosaccharomyces pombe dim1 + Gene Interacts with the Anaphase-Promoting Complex or Cyclosome (APC/C) Component lid1 + and Is Required for APC/C Function

Characteristics and outcomes of patients (pts) with metastatic KRAS mutant lung adenocarcinomas: Lung Cancer Mutation Consortium (LCMC) database

Suchergebnisse filtern